Texas Yale Capital Corp. - GLAXOSMITHKLINE PLC ownership

GLAXOSMITHKLINE PLC's ticker is GSK and the CUSIP is 37733W105. A total of 827 filers reported holding GLAXOSMITHKLINE PLC in Q2 2022. The put-call ratio across all filers is 0.47 and the average weighting 0.3%.

Quarter-by-quarter ownership
Texas Yale Capital Corp. ownership history of GLAXOSMITHKLINE PLC
ValueSharesWeighting
Q2 2022$262,000
+4.0%
6,010
+4.0%
0.02%
+21.4%
Q1 2022$252,000
+7.7%
5,780
+8.9%
0.01%
+16.7%
Q4 2021$234,000
+17.0%
5,310
+1.3%
0.01%
+9.1%
Q3 2021$200,000
-46.7%
5,240
-43.3%
0.01%
-65.6%
Q3 2017$375,000
-2.8%
9,247
+3.3%
0.03%
-5.9%
Q2 2017$386,000
+2.4%
8,9500.0%0.03%
+3.0%
Q1 2017$377,000
+9.3%
8,9500.0%0.03%0.0%
Q4 2016$345,000
-57.0%
8,950
-51.9%
0.03%
-57.1%
Q3 2016$802,000
-21.6%
18,600
-21.2%
0.08%
-24.5%
Q2 2016$1,023,000
+95.6%
23,600
+82.9%
0.10%
+88.9%
Q1 2016$523,000
+0.4%
12,9000.0%0.05%
+8.0%
Q4 2015$521,000
+5.0%
12,9000.0%0.05%
+6.4%
Q3 2015$496,000
+12.5%
12,900
+21.7%
0.05%
+27.0%
Q2 2015$441,000
+70.9%
10,600
+89.3%
0.04%
+76.2%
Q1 2015$258,000
+7.9%
5,6000.0%0.02%0.0%
Q4 2014$239,000
-53.5%
5,600
-50.0%
0.02%
-22.2%
Q3 2014$514,000
+71.9%
11,200
+100.0%
0.03%
-27.0%
Q2 2014$299,000
-47.2%
5,600
-47.2%
0.04%
-7.5%
Q1 2014$566,000
+100.0%
10,600
+100.0%
0.04%
-7.0%
Q4 2013$283,000
+6.4%
5,3000.0%0.04%
-4.4%
Q3 2013$266,000
+0.4%
5,3000.0%0.04%
-2.2%
Q2 2013$265,0005,3000.05%
Other shareholders
GLAXOSMITHKLINE PLC shareholders Q2 2022
NameSharesValueWeighting ↓
Healthcare Value Capital, LLC 100,000$3,680,00012.40%
Black Creek Investment Management Inc. 7,443,061$273,905,0008.54%
KAHN BROTHERS GROUP INC 1,281,924$47,174,803,0008.23%
Camber Capital Management LP 3,500,000$128,800,0004.52%
Eversept Partners, LP 946,581$35,196,5224.13%
EQUITY INVESTMENT CORP 2,321,164$85,419,0003.98%
Galibier Capital Management Ltd. 575,741$21,187,0003.66%
Keystone Financial Planning, Inc. 217,399$8,000,0003.32%
CLIFFORD CAPITAL PARTNERS LLC 217,817$8,016,0003.14%
CLARK ESTATES INC/NY 485,000$17,848,0002.52%
View complete list of GLAXOSMITHKLINE PLC shareholders